Drugs Made In America Acquisition II Corp. (DMII): Operating Income

Annual figures by period end, from SEC filings.

-$488.4K

Year ended 2025-12-31

-$635.2K

Trailing 12 months to 2026-06-30

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$488.4K	n/a	2026-04-15, From 2025-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Blank Checks), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Drugs Made In America Acquisition II Corp. (DMII)	2025-12-31	-$488.4K	n/a
EQV Ventures Acquisition Corp. II (EVAC)	2025-12-31	-$742.3K	n/a
Cantor Equity Partners IV, Inc. (CEPF)	2025-12-31	-$293.9K	n/m
Innventure, Inc. (INV)	2025-12-31	-$464.70M	n/a
Gores Holdings X, Inc. (GTEN)	2025-12-31	-$1.85M	n/a
New Providence Acquisition Corp. III/Cayman (NPAC)	2025-12-31	-$669.4K	n/a
Berto Acquisition Corp. (TACO)	2025-12-31	-$647.4K	n/a
GP-Act III Acquisition Corp. (GPAT)	2025-12-31	-$551.9K	n/m
WEN Acquisition Corp (WENN)	2025-12-31	-$756.7K	n/a

Compare DMII, EVAC, CEPF, INV side by side · Screen every company in Blank Checks ↗